AstraZeneca invests $2B in Summit to pair cancer ADCs with bispecific antibody
What's the deal? AstraZenecaDealroom has a profile for this one. Try Dealroom → has agreed to invest $2 billion in newly issued equity in Summit TherapeuticsDealroom has a profile for this one. Try Dealroom → to speed development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates (ADCs). The companies also signed a clinical collaboration to test ivonescimab alongside AstraZeneca's sonesitatug vedotin (Sone-Ve), a CLDN18.2-targeting ADC, in gastrointestinal cancers.
By the numbers: The $2 billion post-IPO equity round ranks in the top 1% of all US health post-IPO equity rounds on record, based on a sample of 3,834 comparable deals.
What's the endgame? Each company will contribute its own medicine to the planned combination trials and share the costs, while keeping development and commercial rights to their respective drugs. The two firms also signed a memorandum of understanding to build a global programme combining ivonescimab with AstraZeneca cancer medicines, including additional ADCs.
Why now? AstraZeneca recently reported positive high-level results from the CLARITY-Gastric01 trial for Sone-Ve in second- and later-line Claudin18.2-positive advanced gastric cancers, showing a statistically significant improvement in overall survival versus investigator's choice of therapy. Those results will be presented at the European Society for Medical Oncology Congress 2026. The companies plan to start GI cancer trials under the collaboration imminently.
What they're saying: "This opportunity to combine ivonescimab with AstraZeneca's ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape," said Susan Galbraith, executive vice president, oncology haematology R&D, AstraZeneca.
Maky Zanganeh, president and co-chief executive officer of Summit, called the deal "an exciting new chapter in the advancement of ivonescimab."
Context: Ivonescimab was engineered by AkesoDealroom has a profile for this one. Try Dealroom → and combines immunotherapy through PD-1 blockade with the anti-angiogenesis effects of blocking VEGF in a single molecule. Summit holds exclusive rights to develop and commercialise it in major territories outside China; Akeso retains rights in China and other regions. The drug is approved for certain non-small cell lung cancer patients in China, and a US Biologics License Application for EGFR-mutated NSCLC is under FDA review.
The signal: The investment underlines a growing industry bet that bispecific antibodies targeting PD-1 and VEGF can improve on current immunotherapies, particularly in lung, breast, and gastrointestinal cancers. By pairing them with ADCs across tumour types, AstraZeneca is positioning combination regimens — not single agents — as the next competitive front in oncology.
Read more: astrazeneca.com
Image credit: Generated with Gemini
